These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 36800830

  • 21. JAK2, MPL, and CALR mutations in Chinese Han patients with essential thrombocythemia.
    Wang J, Zhang B, Chen B, Zhou RF, Zhang QG, Li J, Yang YG, Zhou M, Shao XY, Xu Y, Xu XH, Ouyang J, Xu J, Ye Q.
    Hematology; 2017 Apr; 22(3):145-148. PubMed ID: 27875935
    [Abstract] [Full Text] [Related]

  • 22. [Analysis of CALR, JAK2 and MPL gene mutations in BCR-ABL negative myeloproliferative neoplasms].
    Ouyang Y, Qiao C, Wang J, Xiao L, Zhang S.
    Zhonghua Yi Xue Za Zhi; 2015 May 12; 95(18):1369-73. PubMed ID: 26178351
    [Abstract] [Full Text] [Related]

  • 23. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
    Ha JS, Kim YK.
    Ann Lab Med; 2015 Jan 12; 35(1):22-7. PubMed ID: 25553276
    [Abstract] [Full Text] [Related]

  • 24. Somatic mutations of calreticulin in myeloproliferative neoplasms.
    Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schönegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R.
    N Engl J Med; 2013 Dec 19; 369(25):2379-90. PubMed ID: 24325356
    [Abstract] [Full Text] [Related]

  • 25. JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.
    Kim BH, Cho YU, Bae MH, Jang S, Seo EJ, Chi HS, Choi Y, Kim DY, Lee JH, Lee JH, Lee KH, Park YM, Lee JK, Park CJ.
    J Korean Med Sci; 2015 Jul 19; 30(7):882-8. PubMed ID: 26130950
    [Abstract] [Full Text] [Related]

  • 26. Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms.
    Trung NT, Quyen DT, Hoan NX, Giang DP, Trang TTH, Velavan TP, Bang MH, Song LH.
    BMC Med Genet; 2019 Jun 27; 20(1):115. PubMed ID: 31248375
    [Abstract] [Full Text] [Related]

  • 27. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A, Barbui T.
    Am J Hematol; 2017 Jan 27; 92(1):94-108. PubMed ID: 27991718
    [Abstract] [Full Text] [Related]

  • 28. A Comparison of Two Molecular Methods for Detecting CALR Mutations in Myeloproliferative Neoplasms.
    Chan TH, Wang YY, Chen CC, Huang WL, Lin IY, Er TK.
    Clin Lab; 2021 Sep 01; 67(9):. PubMed ID: 34542973
    [Abstract] [Full Text] [Related]

  • 29. [Clinical significance of JAK2、CALR and MPL gene mutations in 1 648 Philadelphia chromosome negative myeloproliferative neoplasms patients from a single center].
    Li MY, Chao HY, Sun AN, Qiu HY, Jin ZM, Tang XW, Han Y, Fu CC, Chen SN, Wu DP.
    Zhonghua Xue Ye Xue Za Zhi; 2017 Apr 14; 38(4):295-300. PubMed ID: 28468090
    [Abstract] [Full Text] [Related]

  • 30. Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms.
    Misawa K, Yasuda H, Araki M, Ochiai T, Morishita S, Shirane S, Edahiro Y, Gotoh A, Ohsaka A, Komatsu N.
    Int J Hematol; 2018 Jun 14; 107(6):673-680. PubMed ID: 29464483
    [Abstract] [Full Text] [Related]

  • 31. The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
    Wu Z, Zhang X, Xu X, Chen Y, Hu T, Kang Z, Li S, Wang H, Liu W, Ma X, Guan M.
    J Hematol Oncol; 2014 Jul 15; 7():48. PubMed ID: 25023898
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Detection and Diagnostic Values of JAK2, CALR, MPL Gene Mutations in 208 Cases of BCR/ABL1 Negative Chronic Myeloproliferative Diseases].
    Li ZL, Gao L, Zhang H, Zhang CX, Chen YR, Huang FZ, Gong M, Gao YY, Tang Y, Ma YG.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug 15; 26(4):1122-1128. PubMed ID: 30111418
    [Abstract] [Full Text] [Related]

  • 34. Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia.
    Usseglio F, Beaufils N, Calleja A, Raynaud S, Gabert J.
    J Mol Diagn; 2017 Jan 15; 19(1):92-98. PubMed ID: 27855276
    [Abstract] [Full Text] [Related]

  • 35. Molecular testing for JAK2, MPL, and CALR in myeloproliferative neoplasms.
    Xia D, Hasserjian RP.
    Am J Hematol; 2016 Dec 15; 91(12):1277-1280. PubMed ID: 27727468
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Clinical and hematological relevance of JAK2 V617F and CALR mutations in BCR-ABL-negative ET patients.
    Limsuwanachot N, Rerkamnuaychoke B, Chuncharunee S, Pauwilai T, Singdong R, Rujirachaivej P, Chareonsirisuthigul T, Siriboonpiputtana T.
    Hematology; 2017 Dec 15; 22(10):599-606. PubMed ID: 28406068
    [Abstract] [Full Text] [Related]

  • 38. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.
    Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, Gangat N, Fjerza R, Belachew AA, Lasho TL, Ketterling RP, Hanson CA, Rambaldi A, Finazzi G, Thiele J, Barbui T, Pardanani A, Vannucchi AM.
    Blood; 2014 Oct 16; 124(16):2507-13; quiz 2615. PubMed ID: 25037629
    [Abstract] [Full Text] [Related]

  • 39. Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.
    Frawley T, O'Brien CP, Conneally E, Vandenberghe E, Percy M, Langabeer SE, Haslam K.
    Genet Test Mol Biomarkers; 2018 Feb 16; 22(2):98-103. PubMed ID: 29323541
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.